Source: Virtual Congress 2020 – Interstitial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Wells (London, United Kingdom). Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options. Virtual Congress 2020 – Interstitial lung diseases

Member's Comments

No comment yet.

Related content which might interest you: Chronic Hypersensitivity Pneumonitis and mortality: impact of comorbidities Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases Year: 2020 Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017 Prognostic factors in chronic hypersensitivity pneumonitis Source: Eur Respir Rev, 29 (156) 190167; 10.1183/16000617.0167-2019 Year: 2020 Risk factors and treatment outcomes in patients with chronic pulmonary aspergillosis Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections Year: 2016 Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis Source: Virtual Congress 2020 – Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis Year: 2020 Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification? Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Scleroderma lung disease: Risk factors and treatment options Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Hypersensitivity pneumonitis: diagnostic mistakes Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Hypersensitivity pneumonitis: current concepts Source: Eur Respir J 2001; 18: 81S-92S Year: 2001 Diagnosis, course and management of hypersensitivity pneumonitis Source: Eur Respir Rev, 31 (163) 210169; 10.1183/16000617.0169-2021 Year: 2022 Occupational hypersensitivity pneumonitis: classical and novel causes and diagnostic approaches Source: International Congress 2019 – PG13 Traditional and modern clinical approaches for diagnosis and management of occupational airways diseases Year: 2019 Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Impact Prognostic impact of comorbidities in patients with chronic Hypersensitivity Pneumonitis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Prognostic factors in Korean patients with chronic hypersensitivity pneumonitis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Prevalance and outcomes of pulmonary hypertension in chronic hypersensitivity pneumonitis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Interstitial pneumonia with autoimmune features: challenges and controversies Source: Eur Respir Rev, 30 (162) 210177; 10.1183/16000617.0177-2021 Year: 2021 Hypersensitivity pneumonitis associated with the use of temozolomide Source: Eur Respir J 2009; 33: 931-934 Year: 2009 Prognostic characteristics in chronic hypersensitivity pneumonitis. Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Hypersensitivity pneumonitis Source: School Course 2014 - Interstitial lung diseases Year: 2014